Literature DB >> 21865397

Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.

Pinghuang Liu1, R Glenn Overman, Nicole L Yates, S Munir Alam, Nathan Vandergrift, Yue Chen, Frederik Graw, Stephanie A Freel, John C Kappes, Christina Ochsenbauer, David C Montefiori, Feng Gao, Alan S Perelson, Myron S Cohen, Barton F Haynes, Georgia D Tomaras.   

Abstract

Understanding the interactions between human immunodeficiency virus type 1 (HIV-1) virions and antibodies (Ab) produced during acute HIV-1 infection (AHI) is critical for defining antibody antiviral capabilities. Antibodies that bind virions may prevent transmission by neutralization of virus or mechanically prevent HIV-1 migration through mucosal layers. In this study, we quantified circulating HIV-1 virion-immune complexes (ICs), present in approximately 90% of AHI subjects, and compared the levels and antibody specificity to those in chronic infection. Circulating HIV-1 virions coated with IgG (immune complexes) were in significantly lower levels relative to the viral load in acute infection than in chronic HIV-1 infection. The specificities of the antibodies in the immune complexes differed between acute and chronic infection (anti-gp41 Ab in acute infection and anti-gp120 in chronic infection), potentially suggesting different roles in immunopathogenesis for complexes arising at different stages of infection. We also determined the ability of circulating IgG from AHI to bind infectious versus noninfectious virions. Similar to a nonneutralizing anti-gp41 monoclonal antibody (MAb), purified plasma IgG from acute HIV-1 subjects bound both infectious and noninfectious virions. This was in contrast to the neutralizing antibody 2G12 MAb that bound predominantly infectious virions. Moreover, the initial antibody response captured acute HIV-1 virions without selection for different HIV-1 envelope sequences. In total, this study demonstrates that the composition of immune complexes are dynamic over the course of HIV-1 infection and are comprised initially of antibodies that nonselectively opsonize both infectious and noninfectious virions, likely contributing to the lack of efficacy of the antibody response during acute infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865397      PMCID: PMC3194959          DOI: 10.1128/JVI.05601-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

Authors:  Daniel A Calarese; Hing-Ken Lee; Cheng-Yuan Huang; Michael D Best; Rena D Astronomo; Robyn L Stanfield; Hermann Katinger; Dennis R Burton; Chi-Huey Wong; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-07       Impact factor: 11.205

3.  Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

Authors:  P N Nyambi; H A Mbah; S Burda; C Williams; M K Gorny; A Nádas; S Zolla-Pazner
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Is human immunodeficiency virus RNA load composed of neutralized immune complexes?

Authors:  Ferdinando Dianzani; Guido Antonelli; Elisabetta Riva; Ombretta Turriziani; Laura Antonelli; Stephen Tyring; Daniel A Carrasco; Hung Lee; Derrick Nguyen; Jingzhi Pan; Joyce Poast; Miles Cloyd; Samuel Baron
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

5.  Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Authors:  Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

6.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Authors:  Brandon F Keele; Elena E Giorgi; Jesus F Salazar-Gonzalez; Julie M Decker; Kimmy T Pham; Maria G Salazar; Chuanxi Sun; Truman Grayson; Shuyi Wang; Hui Li; Xiping Wei; Chunlai Jiang; Jennifer L Kirchherr; Feng Gao; Jeffery A Anderson; Li-Hua Ping; Ronald Swanstrom; Georgia D Tomaras; William A Blattner; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Myron S Cohen; David C Montefiori; Barton F Haynes; Brian Gaschen; Gayathri S Athreya; Ha Y Lee; Natasha Wood; Cathal Seoighe; Alan S Perelson; Tanmoy Bhattacharya; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

7.  Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Authors:  S Munir Alam; Richard M Scearce; Robert J Parks; Kelly Plonk; Steven G Plonk; Laura L Sutherland; Miroslaw K Gorny; Susan Zolla-Pazner; Stacie Vanleeuwen; M Anthony Moody; Shi-Mao Xia; David C Montefiori; Georgia D Tomaras; Kent J Weinhold; Salim Abdool Karim; Charles B Hicks; Hua-Xin Liao; James Robinson; George M Shaw; Barton F Haynes
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

8.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  High throughput functional analysis of HIV-1 env genes without cloning.

Authors:  Jennifer L Kirchherr; Xiaozhi Lu; Webster Kasongo; Victor Chalwe; Lawrence Mwananyanda; Rosemary M Musonda; Shi-Mao Xia; Richard M Scearce; Hua-Xin Liao; David C Montefiori; Barton F Haynes; Feng Gao
Journal:  J Virol Methods       Date:  2007-04-09       Impact factor: 2.014

10.  B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells.

Authors:  S Moir; A Malaspina; Y Li; T W Chun; T Lowe; J Adelsberger; M Baseler; L A Ehler; S Liu; R T Davey; J A Mican; A S Fauci
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

View more
  35 in total

1.  Frequencies of Circulating Th1-Biased T Follicular Helper Cells in Acute HIV-1 Infection Correlate with the Development of HIV-Specific Antibody Responses and Lower Set Point Viral Load.

Authors:  Omolara Baiyegunhi; Bongiwe Ndlovu; Funsho Ogunshola; Nasreen Ismail; Bruce D Walker; Thumbi Ndung'u; Zaza M Ndhlovu
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

2.  Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors:  Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

3.  Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.

Authors:  S Munir Alam; Hua-Xin Liao; Georgia D Tomaras; Mattia Bonsignori; Chun-Yen Tsao; Kwan-Ki Hwang; Haiyan Chen; Krissey E Lloyd; Cindy Bowman; Laura Sutherland; Thomas L Jeffries; Daniel M Kozink; Shelley Stewart; Kara Anasti; Frederick H Jaeger; Robert Parks; Nicole L Yates; R Glenn Overman; Faruk Sinangil; Phillip W Berman; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Nicos Karasavva; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Susan Zolla-Pazner; Sampa Santra; Norman L Letvin; Stephen C Harrison; Barton F Haynes
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

4.  The size and composition of circulating immune complexes during HIV infection.

Authors:  L B Korolevskaya; K V Shmagel; N G Shmagel; V A Chereshnev
Journal:  Dokl Biochem Biophys       Date:  2014-08-30       Impact factor: 0.788

5.  Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.

Authors:  Pinghuang Liu; Latonya D Williams; Xiaoying Shen; Mattia Bonsignori; Nathan A Vandergrift; R Glenn Overman; M Anthony Moody; Hua-Xin Liao; Daniel J Stieh; Kerrie L McCotter; Audrey L French; Thomas J Hope; Robin Shattock; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

6.  A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities.

Authors:  Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

7.  Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.

Authors:  Bonnie Phillips; Genevieve G Fouda; Josh Eudailey; Justin Pollara; Alan D Curtis; Erika Kunz; Maria Dennis; Xiaoying Shen; Camden Bay; Michael Hudgens; David Pickup; S Munir Alam; Amir Ardeshir; Pamela A Kozlowski; Koen K A Van Rompay; Guido Ferrari; M Anthony Moody; Sallie Permar; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-10-05

8.  HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Authors:  Justin Pollara; Mattia Bonsignori; M Anthony Moody; Pinghuang Liu; S Munir Alam; Kwan-Ki Hwang; Thaddeus C Gurley; Daniel M Kozink; Lawrence C Armand; Dawn J Marshall; John F Whitesides; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Robert J O'Connell; Jerome H Kim; Nelson L Michael; David C Montefiori; Georgia D Tomaras; Hua-Xin Liao; Barton F Haynes; Guido Ferrari
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

Review 10.  HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.

Authors:  Mattia Bonsignori; S Munir Alam; Hua-Xin Liao; Laurent Verkoczy; Georgia D Tomaras; Barton F Haynes; M Anthony Moody
Journal:  Trends Microbiol       Date:  2012-09-13       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.